Merck back to profits on lower one-time costs

August 6, 2013

German drug and high-tech materials company Merck KGaA bounced back from losses this time last year to record a net profit of 316 million euros ($420 million) in the second quarter.

The Darmstadt-based company, which produces the liquid crystal used in TV screens and life sciences laboratory equipment, lost 63 million euros in the year-ago quarter when it had 376 million euros in expenses for its restructuring and cost-cutting program. The April-June profit figures beat for 277 million euros, according to financial information provider FactSet.

Merck said Tuesday it was benefiting from its cost-cutting program, adding that it would make its earnings goal for all of 2013. Sales increased strongly for its liquid crystal materials used in flat-screen TVs, mobile phones and digital cameras. However, the company cautioned that customer inventories of liquid crystal materials had risen, meaning demand could slacken in the second half of the year.

The company also saw higher prices for its Rebif treatment for multiple sclerosis after it became available in a single-dose portable injector. Rebif is used to decrease the number of flare-ups of some forms of MS and to delay common in people with the disease.

Revenue fell 0.4 percent to 2.84 billion euros. Revenues would have risen without the negative effect amounting to 3.4 percent from the recently weaker yen, which shrinks Japan earnings when they are translated into euro currency terms. Merck shares fell 3.6 percent to 121.50 euros in morning trading in Europe.

Merck KGaA is different from Merck & Co., Inc. in the United States.

Explore further: Merck Q4 net profit more than doubles

Related Stories

Merck Q4 net profit more than doubles

March 7, 2013

Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.

Generic competition cuts Merck's Q1 sales, profit

May 1, 2013

Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Higher prices for MS drug help drug firm Merck

May 14, 2013

(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.

Bayer Q2 profits jump on new drugs, lower charges (Update)

July 31, 2013

German drug and chemicals company Bayer AG says net profit rose 75 percent in the second quarter thanks to lower one-time charges and strong sales of new products including anti-clotting drug Xarelto and cancer drug Stivarga.

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.